OPKO Health stock: Piper Sandler lifts target for OPKO Health stock to USD 4.00

Published on 10/23/2026 at 04:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Piper Sandler raised its target to USD 4.00 on October 16, 2026. OPKO Health stock posted USD 163.58 million in second-quarter revenue.

Transaction and reporting milestones

Labcorp agreed on October 15, 2026, to pay USD 722 million for selected BioReference assets.
Piper Sandler lifted its OPKO Health target from USD 3.00 to USD 4.00 on October 16, 2026.
OPKO Health is expected to report third-quarter results on October 28, 2026.

OPK, US68375N1037, Illustration mit AI erstellt.

OPKO Health (ISIN US68375N1037) became the subject of a higher analyst target after Piper Sandler lifted its view from USD 3.00 to USD 4.00 on October 16, 2026, according to Markets Insider. The revision followed OPKO Health's agreement to sell selected BioReference Health assets to Labcorp.

USD 722 million deal reshapes OPKO

Under the agreement announced on October 15, 2026, Labcorp will pay USD 722 million in cash at closing for selected laboratory testing operations and related assets. The transaction also provides for up to USD 150 million in earnout payments tied to revenue from the 4Kscore prostate cancer test, according to OPKO Health.

The assets include clinical, women's health, urology and corrections testing businesses, plus more than 80 patient service centers and the 4Kscore test. OPKO said the sale would streamline operations and direct resources toward its biopharmaceutical business, while regulatory approvals and customary closing conditions remain part of the process.

Three milestones set the valuation debate

On October 2, 2026, OPKO disclosed that approximately USD 121 million of convertible notes could be converted through December 31, 2026, with the company electing to settle conversion obligations in common stock, according to OPKO Health. The filing said the conversion condition required the stock to exceed USD 1.495 for at least 20 of 30 consecutive trading days during the quarter ended September 30, 2026.

The October 15 transaction and the October 16 target increase form the latest sequence. Piper Sandler kept an Overweight rating while raising its target to USD 4.00, and Barrington Research separately moved OPKO from Market Perform to Outperform with a USD 2.25 target, according to MarketBeat.

What does the sale mean for results?

OPKO reported USD 163.58 million in revenue for the second quarter of 2026, up 4.30 percent year over year, while net loss attributable to common shareholders was USD 8.42 million. The proceeds and the shift toward biopharmaceuticals give investors a concrete measure for judging whether the transaction improves the company's financial flexibility.

Dates for results and conversion

OPKO's next estimated earnings date is October 28, 2026, according to Yahoo Finance. The convertible notes remain eligible for conversion through December 31, 2026, under the company's October 2 filing.

Nasdaq context and company scale

OPKO Health is listed on the Nasdaq Global Select Market under ticker OPK. The last quoted Nasdaq value was USD 1.63 on October 22, 2026 at 4:00 p.m. ET. Its market capitalization was USD 1.2 billion and its 52-week range was USD 0.98 to USD 1.77 as of October 22, 2026.

OPKO Health also reported cash of USD 300.76 million as of June 30, 2026. The company operates pharmaceutical and diagnostics businesses, so the asset sale changes the balance between laboratory operations and drug development rather than ending either activity. The further course of trading is shown by the continuously updated real-time quote of OPKO Health stock.